Form 4: Cue Biopharma CFO Kerri-Ann Millar Granted Stock Options

Kerri-Ann Millar, CFO of Cue Biopharma, Inc., was granted stock options to purchase 250,000 shares of common stock at an exercise price of $1.94 on March 6, 2024.

Summary

• On March 6, 2024, Kerri-Ann Millar, the Chief Financial Officer of Cue Biopharma, Inc., was granted stock options.
• These options allow Millar to purchase 250,000 shares of Cue Biopharma's common stock at an exercise price of $1.94 per share.
• The stock options vest in eight equal semi-annual installments, starting on September 6, 2024.
• The options expire on March 5, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders.

Positives

• The granting of stock options to the CFO aligns her interests with those of the shareholders.
• The vesting schedule incentivizes long-term commitment from the CFO.

Future Outlook

The document does not contain any specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Granting stock options to key executives is a common practice in the biopharmaceutical industry to incentivize performance and retain talent. This aligns with standard compensation practices in similar companies.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotechnology industry.
• Comparable companies like BioNTech or Moderna also utilize stock options to incentivize their executives.
• The vesting schedule of semi-annual installments over four years is a fairly standard practice.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the CFO to drive company performance.
• Employees may see this as a sign of confidence in the company's future.

Key Dates